Yes, but as others have said, professional advancement typically depends on publishing in the expensive journals. And that's no accident, in that predatory for-profit publishers have targeted prestigious journals for acquisition. It's the same game that drug makers play with top-selling drugs.

Eventually, authors will migrate to the not-for-profit open access journals and platforms. But that will take time. Top-ranked PIs must lead the way, given that their reputations are well established, and they have tenure.